These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 9244846)

  • 21. [C-reactive protein in cardiovascular risk evaluation].
    Fabijanić D; Banić M; Kardum D
    Lijec Vjesn; 2006; 128(5-6):167-74. PubMed ID: 16910418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Inflammation and C-reactive protein in cardiovascular disease].
    Munk PS; Larsen AI
    Tidsskr Nor Laegeforen; 2009 Jun; 129(12):1221-4. PubMed ID: 19521445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial.
    Woodward M; Lowe GD; Francis LM; Rumley A; Cobbe SM;
    J Thromb Haemost; 2004 Nov; 2(11):1934-40. PubMed ID: 15550024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of inflammation and coagulation after infusion of C-reactive protein in humans.
    Bisoendial RJ; Kastelein JJ; Levels JH; Zwaginga JJ; van den Bogaard B; Reitsma PH; Meijers JC; Hartman D; Levi M; Stroes ES
    Circ Res; 2005 Apr; 96(7):714-6. PubMed ID: 15774855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prolonged application of clopidogrel reduces inflammation after percutaneous coronary intervention in the porcine model.
    Ayral Y; Rauch U; Goldin-Lang P; Stellbaum C; Deiner C; Schwimmbeck PL; Schultheiss HP; Pels K
    Cardiovasc Revasc Med; 2007; 8(3):183-8. PubMed ID: 17765648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of aspirin on serum C-reactive protein and interleukin-6 levels in patients with type 2 diabetes without cardiovascular disease: a randomized placebo-controlled crossover trial.
    Hovens MM; Snoep JD; Groeneveld Y; Frölich M; Tamsma JT; Huisman MV
    Diabetes Obes Metab; 2008 Aug; 10(8):668-74. PubMed ID: 18034847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. C-reactive protein: a novel marker of cardiovascular risk.
    Shah SH; Newby LK
    Cardiol Rev; 2003; 11(4):169-79. PubMed ID: 12852794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit.
    Ridker PM
    Am Heart J; 2004 Jul; 148(1 Suppl):S19-26. PubMed ID: 15211329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of aspirin-induced decrease in thrombin formation in subjects resistant to aspirin.
    Undas A; Placzkiewicz-Jankowska E; Zieliński L; Tracz W
    Thromb Haemost; 2007 Jun; 97(6):1056-8. PubMed ID: 17549314
    [No Abstract]   [Full Text] [Related]  

  • 30. Inflammation, coagulation, and depressive symptomatology in cardiovascular disease-free people; the ATTICA study.
    Panagiotakos DB; Pitsavos C; Chrysohoou C; Tsetsekou E; Papageorgiou C; Christodoulou G; Stefanadis C;
    Eur Heart J; 2004 Mar; 25(6):492-9. PubMed ID: 15039129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perspectives on aspirin, part 2: aspirin as an anticoagulant--potentials for risk and benefit.
    Plein JB
    Nurse Pract; 1976; 1(5):31-3. PubMed ID: 1046568
    [No Abstract]   [Full Text] [Related]  

  • 32. JUPITER study highlights C-reactive protein as a cardiac risk factor.
    Cardiovasc J Afr; 2009; 20(2):146. PubMed ID: 19421655
    [No Abstract]   [Full Text] [Related]  

  • 33. What can we expect from omega-3 fatty acids?
    Chan EJ; Cho L
    Cleve Clin J Med; 2009 Apr; 76(4):245-51. PubMed ID: 19339640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure.
    Joynt KE; Gattis WA; Hasselblad V; Fuzaylov SY; Serebruany VL; Gurbel PA; Gaulden LH; Felker GM; Whellan DJ; O'Connor CM
    Am J Cardiol; 2004 Mar; 93(6):783-5. PubMed ID: 15019895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aspirin resistance: what, why and when?
    Shantsila E; Watson T; Lip GY
    Thromb Res; 2007; 119(5):551-4. PubMed ID: 17010411
    [No Abstract]   [Full Text] [Related]  

  • 36. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
    Moyad MA
    Semin Urol Oncol; 2001 Nov; 19(4):294-305. PubMed ID: 11769881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aspirin for primary prevention of cardiovascular disease (revisited).
    Med Lett Drugs Ther; 2006 Jul; 48(1238):53. PubMed ID: 16841021
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
    Greving JP; Buskens E; Koffijberg H; Algra A
    Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Aspirin therapy for cardiovascular prevention in the diabetic patient: what have we learned from the evidence?].
    Legrand DA; Scheen AJ
    Rev Med Suisse; 2006 Aug; 2(76):1904-8. PubMed ID: 16972540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of long-term nicorandil administration on endothelial function, inflammation, and oxidative stress in patients without coronary artery disease.
    Ishibashi Y; Takahashi N; Tokumaru A; Karino K; Sugamori T; Sakane T; Yoshitomi H; Sato H; Oyake N; Murakami Y; Shimada T
    J Cardiovasc Pharmacol; 2008 Mar; 51(3):311-6. PubMed ID: 18356697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.